ASCO 2010 Intro

News
Article

Watch this page for ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists give exclusive interviews and expert perspective reports of the highlights of this year’s meeting.

Advancing quality through innovation

 

Watch this page for ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists give exclusive interviews and expert perspective reports of the highlights of this year’s meeting.

 

GI cancer specialists

Richard M. Goldberg, MD, Lineberger Comprehensive Cancer Center and Peter C. Enzinger, MD, Dana-Farber Cancer Institute

Renal cell carcinoma experts

Andrew J. Armstrong, MD, MSc, Duke Comprehensive Cancer Center, and Robert J. Motzer, MD, MSKK

Hematologic malignancy authority

Samuel M. Silver, MD, PhD, University of Michigan

Our coverage will include the most clinically relevant educational seminars, on-site sessions, abstracts, and breaking news. Please stay tuned over the next several weeks for the best of this year’s exciting meeting.

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
4 experts in this video
2 experts in this video
Related Content
The recommendation from the CHMP is based on results from the phase 2b HERIZON-BTC-01 trial of zanidatamab in advanced HER2+ biliary tract cancer.

Zanidatamab Recommended For Conditional Marketing Approval in Advanced HER2+ BTC

Roman Fabbricatore
April 29th 2025
Article

The recommendation from the CHMP is based on results from the phase 2b HERIZON-BTC-01 trial of zanidatamab in advanced HER2+ biliary tract cancer.

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

William R. Kennedy, MD
April 28th 2025
Podcast

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Nurulimab/Prolgolimab Yield Superior Efficacy in Advanced Melanoma

Nurulimab/Prolgolimab Yield Superior Efficacy in Advanced Melanoma

Ariana Pelosci
April 28th 2025
Article

The combination of nurulimab plus prolgolimab enhanced PFS, ORR, and DCR compared with prolgolimab monotherapy in unresectable or metastatic melanoma.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.

Same-Day G-CSF After Chemo Appears Safe, Efficacious in Breast Cancer

Roman Fabbricatore
April 28th 2025
Article

No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.

Frailty Assessments Indicate Severe AE Probability in Prostate Cancer

Frailty Assessments Indicate Severe AE Probability in Prostate Cancer

Tim Cortese
April 28th 2025
Article

BMI, serum albumin, and G8 screening tool scores were all factors correlated with the likelihood of experiencing a grade 3 or higher AE.